株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アジア太平洋地域の呼吸器合胞体ウイルス (RSV) の疫学的予測

Respiratory Syncytial Virus: Epidemiology Forecast in Asia-Pacific Markets to 2028

発行 GlobalData 商品コード 915015
出版日 ページ情報 英文 43 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
アジア太平洋地域の呼吸器合胞体ウイルス (RSV) の疫学的予測 Respiratory Syncytial Virus: Epidemiology Forecast in Asia-Pacific Markets to 2028
出版日: 2019年10月31日 ページ情報: 英文 43 Pages
概要

当レポートでは、アジア太平洋地域の主要5ヶ国 (日本、オーストラリア、中国 (都市部)、インド、韓国) における呼吸器合胞体ウイルス (RSウイルス、RSV) の発症状況と今後の見通しについて分析し、疾患の特徴や、現在の有病者の発症状況、今後10年間の有病件数の予測値などを調査しております。

第1章 目次

第2章 呼吸器合胞体ウイルス (RSV):エグゼクティブサマリー

  • 関連分析
  • 刊行予定の関連分析

第3章 疫学

  • 疾患の背景事情
  • リスク要因と共存症
  • 過去の世界的傾向
  • 予測手法
    • 利用した/しなかった情報源
    • 予測の前提条件と手法
  • RSV入院患者数:疫学的予測 (今後11年間分)
    • 成人のRSV入院患者数:RSV検査で陽性反応だった者
    • 小児のRSV入院患者数 (確定人数)
  • RSV予防接種の利用人数の予測 (今後11年間分)
    • 早産の件数:妊娠期間別
    • 慢性肺疾患 (CLD) を発症している未熟児の人数
    • 血行動態面で重い心疾患を抱えている新生児の人数
    • DMD (デュシェンヌ型筋ジストロフィー) の受診済み有病者数
    • SMA (脊髄性筋萎縮症) の受診済み有病者数
    • 妊娠後期 (第3期) の妊婦の人数
    • 介護施設/長期療養施設で暮らしている成人患者の人数
  • 議論
    • 疫学的予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

List of Tables

  • Table 1: 5GM, Summary of the Prophylactic Population in 2018
  • Table 2: Risk Factors for Severe RSV

List of Figures

  • Figure 1: 5GM, Children, Boys and Girls, 0-2 Years Old, Confirmed RSV Hospitalizations, N, 2008 and 2018
  • Figure 2: 5GM, Rate of Preterm Births (per 1,000 Live Births), 2008-2018
  • Figure 3: 5GM, Percentage of Adults Living in Long-Term Care, Ages ≥55 Years, 2008-2018
  • Figure 4: 5GM, Sources Used to Forecast the Number of Adults Hospitalized Who Test Positive for RSV, 2018-2028
  • Figure 5: 5GM, Sources Used to Forecast the Number of Children Hospitalized with Confirmed RSV
  • Figure 6: 5GM, Sources Used to Forecast the Number of Preterm Births
  • Figure 7: 5GM, Sources Used to Forecast the Number of Preterm Births with CLD, 2018-2028
  • Figure 8: 5GM, Sources Used to Forecast the Number of Live Births with Hemodynamically Significant Heart Disease
  • Figure 9: 5GM, Sources Used to Forecast Diagnosed Prevalent Cases of DMD
  • Figure 10: 5GM, Sources Used to Forecast the Diagnosed Prevalent Cases of SMA
  • Figure 11: 5GM, Sources Used to Forecast the Number of Third Trimester Pregnancies
  • Figure 12: 5GM, Sources Used to Forecast the Number of Adults Living in Long-Term Care
  • Figure 13: 5GM, Number of Hospitalized Adults with Positive RSV Test, Ages ≥60 Years, Men and Women, 2018
  • Figure 14: 5GM, Number of Children Hospitalized for Confirmed RSV, Ages 0-2 Years, Boys and Girls, 2018
  • Figure 15: 5GM, Number of Preterm Births by Gestational Age, N, 2018
  • Figure 16: 5GM, Number of Preterm Infants with CLD, N, 2018-2028
  • Figure 17: 5GM, Number of Live Births with Hemodynamically Significant Heart Disease, 2018-2028
  • Figure 18: 5GM, Diagnosed Prevalent Cases of DMD in Boys, Ages 0-2 Years, 2018-2028
  • Figure 19: 5GM, Diagnosed Prevalent Cases of SMA, Boys and Girls, Ages 0-2 Years, 2018-2028
  • Figure 20: 5GM, Number of Third Trimester Pregnant Women, N, 2018-2028
  • Figure 21: 5GM, Number of Adults Living in Long-Term Care Institutions, Ages ≥55 Years, N, 2018-2028
目次
Product Code: GDHCER217-19

Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. In healthy individuals RSV usually self-resolves within a week or two without need for significant therapeutic intervention. In preterm and very young infants, the elderly, or those with otherwise compromised immune systems, however, RSV can cause severe illness or death.

It has been estimated that up to 30 million episodes of RSV-related lower respiratory infection occur annually worldwide, with the majority of those cases occurring in low-income countries. RSV is also considered to be the leading cause of bronchiolitis and pneumonia in children less than one year old and one of the leading causes of respiratory disease in older adults. Currently RSV has neither a known cure nor a vaccine; however, preventive measures can be taken to help mitigate the spread of the disease

GlobalData epidemiologists provide a well-rounded, evidence-based analysis and forecast for the hospitalized and prophylactic populations for RSV in this report. This analysis covered all at-risk groups that are recommended for RSV prophylactic treatment. Each population, including the hospitalized population, is also segmented by ages and by sex, thereby providing a granular visualization of the RSV prophylactic and hospitalized markets in the 5GM.

Scope:

  • The Respiratory Syncytial Virus (RSV) Epidemiology Report and Model provide an overview of the risk factors and global trends RSV in the five growth markets (5GM: Japan, Australia, urban China, India, and South Korea).
  • This report also includes a 10-year epidemiology forecast for the pediatric and adult populations hospitalized due to RSV infection (hospitalized population) in the 5GM, in addition to the pediatric and adult populations that are most at risk for severe RSV infection and are therefore eligible to receive prophylactic treatment (prophylactic population). The prophylactic population consists of: children born before 37 weeks of gestation (preterm population); preterm births with neonatal chronic lung disease (CLD); live births with hemodynamically significant congenital heart disease; boys, 0-2 years old, with Duchenne muscular dystrophy (DMD); children, 0-2 years old, with spinal muscular atrophy (SMA); pregnant women in the third trimester; adults ages 55 years or older living in nursing homes (long-term-care institutions).
  • The RSV epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 5GM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy:

The RSV Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global RSV market.
  • Quantify patient populations in the global RSV market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RSV therapeutics in each of the markets covered.
  • Understand magnitude of RSV population by both therapeutic and prophylactic markets.

Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Respiratory Syncytial Virus: Executive Summary

  • 2.1. Related Reports
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global and Historical Trends
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used and Not Used
    • 3.4.2. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for RSV Hospitalized Population (2018-2028)
    • 3.5.1. Number of Hospitalized Adults with Positive RSV Test
    • 3.5.2. Number of Children Hospitalized for Confirmed RSV
  • 3.6. Epidemiological Forecast for RSV Prophylactic Population (2018-2028)
    • 3.6.1. Number of Preterm Births by Gestational Age
    • 3.6.2. Preterm Infants with CLD
    • 3.6.3. Number of Live Births with Hemodynamically Significant Heart Disease
    • 3.6.4. Diagnosed Prevalent Cases of DMD
    • 3.6.5. Number of Diagnosed Prevalent Cases of SMA
    • 3.6.6. Number of Third Trimester Pregnant Women
    • 3.6.7. Number of Adults Living in Nursing Homes/Long-Term Care Institutions
  • 3.7. Discussion
    • 3.7.1. Epidemiological Forecast Insight
    • 3.7.2. Limitations of Analysis
    • 3.7.3. Strengths of Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologist
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head and EVP of Healthcare Operations and Strategy
  • 4.3. About GlobalData
  • 4.4. Contact Us
  • 4.5. Disclaimer
Back to Top